文献速递组学、生物样本库与精准医学医学人工智能与信息学基础与转化研究

深度表型年轻新冠队列中鉴定重症驱动基因

Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort.
PubMed 文献 · Sci Transl Med · 2022-01-19

研究在排除主要合并症的年轻COVID-19队列中,用多组学结合人工智能分析47例重症、25例非重症患者及22名健康人,发现重症患者存在炎症加剧、淋巴与髓系区室扰动、凝血增强及病毒细胞生物学改变,并鉴定ADAM9为疾病严重度驱动基因及候选治疗靶点。

要点

  • 重症COVID-19年轻患者存在炎症、免疫区室、凝血及病毒细胞生物学等多层面扰动。
  • ADAM9在重症患者中表达上调,并在独立队列中于转录和蛋白水平验证。
  • 体外抑制ADAM9可减少人肺上皮细胞对SARS-CoV-2的摄取和复制。

核心结论

  • 在无主要合并症的年轻COVID-19队列中,独特的基因特征可区分重症与非重症患者。
  • ADAM9被鉴定为疾病严重度的驱动基因及候选治疗靶点。

研究设计与样本

  • 多组学分析结合人工智能,纳入47例重症(ICU机械通气)、25例非重症COVID-19患者及22名健康人。
  • 分析包括全基因组测序、全血RNA测序、血浆和血单核细胞蛋白质组学、细胞因子谱及高通量免疫表型分析。
  • 使用机器学习、深度学习、量子退火和结构因果建模的集成方法。

主要发现

  • 重症COVID-19患者表现为炎症加剧、淋巴和髓系区室扰动、凝血增加及病毒细胞生物学改变。
  • 差异表达基因中观察到金属蛋白酶ADAM9上调。
  • 该基因特征在第二独立队列(81例重症和73例康复COVID-19患者)中得到验证,并在转录和蛋白水平及蛋白水解活性上进一步确认。
  • 体外抑制ADAM9减少人肺上皮细胞中SARS-CoV-2的摄取和复制。

临床怎么用

  • ADAM9可作为重症COVID-19的候选治疗靶点,值得进一步转化研究。
  • 在年轻无合并症患者中鉴定的基因特征有助于理解重症驱动机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The drivers of critical coronavirus disease 2019 (COVID-19) remain unknown. Given major confounding factors such as age and comorbidities, true mediators of this condition have remained elusive. We used a multi-omics analysis combined with artificial intelligence in a young patient cohort where major comorbidities were excluded at the onset. The cohort included 47 “critical” (in the intensive care unit under mechanical ventilation) and 25 “non-critical” (in a non-critical care ward) patients with COVID-19 and 22 healthy individuals. The analyses included whole-genome sequencing, whole-blood RNA sequencing, plasma and blood mononuclear cell proteomics, cytokine profiling, and high-throughput immunophenotyping. An ensemble of machine learning, deep learning, quantum annealing, and structural causal modeling were used. Patients with critical COVID-19 were characterized by exacerbated inflammation, perturbed lymphoid and myeloid compartments, increased coagulation, and viral cell biology. Among differentially expressed genes, we observed up-regulation of the metalloprotease ADAM9. This gene signature was validated in a second independent cohort of 81 critical and 73 recovered patients with COVID-19 and was further confirmed at the transcriptional and protein level and by proteolytic activity. Ex vivo ADAM9 inhibition decreased severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uptake and replication in human lung epithelial cells. In conclusion, within a young, otherwise healthy, cohort of individuals with COVID-19, we provide the landscape of biological perturbations in vivo where a unique gene signature differentiated critical from non-critical patients. We further identified ADAM9 as a driver of disease severity and a candidate therapeutic target.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Carapito R, Li R, Helms J, et al. Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort. Sci Transl Med. 2022. PMID: 34698500. doi:10.1126/scitranslmed.abj7521

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。